The patch trial was completed. I’ve already seen a descriptive report of the results in PCa Commentary volume 195 November 2024. The final report Is supposed to be released at the next UK conference. An estradiol patch is just as successful as ADT in suppressing testosterone, but had some positive results. It did reduce brain fog.

If you have BRCA2 it cannot be used, estrogen can cause breast cancer.

Here are some of the results

At 3 years metastasis-free survival was the same for both agents ~86 to 87%. Overall survival
was similar over 14 years of follow-up.
- The adverse effects profile favored tE2, reducing hot flushes from 89% (Lupron) to 44% (tE2).
At 2 years bone mineral density improved by 7.9% ( tE2) vs. a -3% worsening for Lupron. This
change occurred rapidly over the first year. tE2 provided an improved quality of life.
- Cardiovascular adverse effects (heart failure, angina and myocardial infarction and
thromboembolic strokes) were similar, about 7-10% . However, gynecomastia developed in
85% (tE2) vs. 44% (Lupron). Prophylactic low-dose radiation to breast tissue lessens this
development.
- Dr. Langley concluded: “Transdermal estrogen provides choice about expected side effects
and route of administration allowing personalized treatment plans. Transdermal estradiol
should be a standard-of-care ADT option in M0 disease.”

Richard Wassersug PhD, Who wrote the book Androgen Deprivation Therapy has been on estradiol patches and Now estradiol gel for a couple years. He’s given talks over at Ancan.org On the use of the estradiol patch. Here’s the link to one of the webinars
https://ancan.org/talking-estradiol-e2-for-recurrent-and-advanced-prostate-cancer/